Palbociclib in the treatment of advanced and/or metastatic hormone‑sensitive HER2‑negative breast cancer

02/2017

MUDr. Tomáš Svoboda, Ph.D.

Onkologická a radioterapeutická klinika LF UK a FN Plzeň

 

SUMMARY

Recently, we have the possibility to use in clinical practice a new targeted drug – palbociclib in the treatment of endocrine receptor positive, HER2 negative breast cancer. In the first line setting of treatment advanced/metastatic disease it is combined with letrozole and in the second line with fulvestrant. Cyclin dependent kinases 4 and 6 (CDK4/6) blockade inhibit the cell cycle progression in G1 phase and is associated with tumor cells proliferation prevention. The drug obtained a very high degree of recommendation and is a part of international guidelines.

 

KEY WORDS

palbociclib, CDK4/6 inhibitor, cell cycle blockade, PALOMA study, aromatase inhibitors, fulvestrant

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM